Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02053636




Registration number
NCT02053636
Ethics application status
Date submitted
24/01/2014
Date registered
4/02/2014
Date last updated
3/01/2020

Titles & IDs
Public title
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Scientific title
An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Secondary ID [1] 0 0
2013-000288-10
Secondary ID [2] 0 0
CL2-80881-001
Universal Trial Number (UTN)
Trial acronym
FINESSE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - lucitanib

Experimental: lucitanib - Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg.
5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent


Treatment: Drugs: lucitanib
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective response rate (ORR)
Timepoint [1] 0 0
Every 8 weeks

Eligibility
Key inclusion criteria
- Histologically confirmed breast adenocarcinoma.

- Presence of an accessible metastatic lesion for biopsy or at least one archived
metastatic tumour sample.

- Prior first-line systemic therapy in the metastatic setting.

- Demonstrated progression of disease by radiological or clinical assessment.

- Female patient, aged =18 years old.

- Estimated life expectancy >3 months.

- Normal Left ventricular function

- Adequate haematological, hepatic and renal functions.

- For women with childbearing potential, a negative pregnancy test prior to initiation
of the study drug and willingness to use an effective contraception.

- Ability to swallow oral capsules or tablets.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- More than two lines of chemotherapy with or without targeted therapy in the metastatic
setting.

- Previous treatment with bevacizumab within 3 months of first dose of Investigational
Medicinal Product.

- Active central nervous system metastases, cerebral oedema, and/or progressive growth.

- Patients with impaired cardiac function.

- Uncontrolled arterial hypertension

- Patients with history of thrombotic disorders or hereditary risk factors of
thromboembolic events

- Serum potassium level below Lower Limit of Normal

- Uncontrolled hypothyroidism.

- Pregnant or breastfeeding women.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/04/2017
Sample size
Target
Accrual to date
Final
76
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Centre - East Melbourne
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
- East Melbourne
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Brussels
Country [2] 0 0
Belgium
State/province [2] 0 0
Bruxelles
Country [3] 0 0
Belgium
State/province [3] 0 0
Charleroi
Country [4] 0 0
Belgium
State/province [4] 0 0
Leuven
Country [5] 0 0
Belgium
State/province [5] 0 0
Namur
Country [6] 0 0
Canada
State/province [6] 0 0
Montreal
Country [7] 0 0
Canada
State/province [7] 0 0
Toronto
Country [8] 0 0
France
State/province [8] 0 0
Toulouse
Country [9] 0 0
France
State/province [9] 0 0
Villejuif Cedex
Country [10] 0 0
France
State/province [10] 0 0
Villejuif
Country [11] 0 0
Germany
State/province [11] 0 0
Essen
Country [12] 0 0
Germany
State/province [12] 0 0
Offenbach
Country [13] 0 0
Hungary
State/province [13] 0 0
Budapest
Country [14] 0 0
Hungary
State/province [14] 0 0
Debrecen
Country [15] 0 0
Italy
State/province [15] 0 0
Milano
Country [16] 0 0
Italy
State/province [16] 0 0
Milan
Country [17] 0 0
Spain
State/province [17] 0 0
Barcelona
Country [18] 0 0
Spain
State/province [18] 0 0
Madrid
Country [19] 0 0
Spain
State/province [19] 0 0
Valencia
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Edinburgh
Country [21] 0 0
United Kingdom
State/province [21] 0 0
London
Country [22] 0 0
United Kingdom
State/province [22] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Other
Name
Institut de Recherches Internationales Servier
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Breast International Group
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The aim of the study is to evaluate the objective response rate (ORR) of single agent
lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified with
11q amplification, or FGFR1-non amplified without 11q amplification.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02053636
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Fabrice André, MD
Address 0 0
Institut Gustave Roussy, France
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02053636